1.5 USD
-0.21 (-12.28%)
1.5 USD
0 (0%)
Taking everything into account, LXRX scores 3 out of 10 in our fundamental rating. LXRX was compared to 190 industry peers in the Pharmaceuticals industry. While LXRX seems to be doing ok healthwise, there are quite some concerns on its profitability. LXRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year LXRX has reported negative net income.
- LXRX had a negative operating cash flow in the past year.
- In the past 5 years LXRX always reported negative net income.
- In the past 5 years LXRX always reported negative operating cash flow.
1.2 Ratios
- LXRX has a Return On Assets (-33.30%) which is comparable to the rest of the industry.
- With a Return On Equity value of -57.07%, LXRX perfoms like the industry average, outperforming 47.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.3% | ||
| ROE | -57.07% | ||
| ROIC | N/A |
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LXRX has a better Gross Margin (99.41%) than 97.37% of its industry peers.
- LXRX's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
- LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for LXRX has been increased compared to 1 year ago.
- Compared to 5 years ago, LXRX has more shares outstanding
- Compared to 1 year ago, LXRX has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -9.94, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
- LXRX has a Altman-Z score of -9.94. This is in the lower half of the industry: LXRX underperforms 71.05% of its industry peers.
- A Debt/Equity ratio of 0.47 indicates that LXRX is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.47, LXRX is not doing good in the industry: 62.63% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.94 |
ROIC/WACCN/A
WACC10.13%
2.3 Liquidity
- A Current Ratio of 5.64 indicates that LXRX has no problem at all paying its short term obligations.
- LXRX's Current ratio of 5.64 is fine compared to the rest of the industry. LXRX outperforms 65.79% of its industry peers.
- LXRX has a Quick Ratio of 5.63. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 5.63, LXRX is in the better half of the industry, outperforming 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.64 | ||
| Quick Ratio | 5.63 |
3. Growth
3.1 Past
- LXRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.67%, which is quite impressive.
- LXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 1255.21%.
- Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)1255.21%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.4%
3.2 Future
- Based on estimates for the next years, LXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
- Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 57.00% on average per year.
EPS Next Y73.38%
EPS Next 2Y26.77%
EPS Next 3Y17.93%
EPS Next 5Y13.37%
Revenue Next Year328.76%
Revenue Next 2Y37.24%
Revenue Next 3Y32.02%
Revenue Next 5Y57%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
- Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as LXRX's earnings are expected to grow with 17.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.77%
EPS Next 3Y17.93%
5. Dividend
5.1 Amount
- LXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
LEXICON PHARMACEUTICALS INC / LXRX FAQ
What is the fundamental rating for LXRX stock?
ChartMill assigns a fundamental rating of 3 / 10 to LXRX.
What is the valuation status of LEXICON PHARMACEUTICALS INC (LXRX) stock?
ChartMill assigns a valuation rating of 0 / 10 to LEXICON PHARMACEUTICALS INC (LXRX). This can be considered as Overvalued.
Can you provide the profitability details for LEXICON PHARMACEUTICALS INC?
LEXICON PHARMACEUTICALS INC (LXRX) has a profitability rating of 2 / 10.
Can you provide the financial health for LXRX stock?
The financial health rating of LEXICON PHARMACEUTICALS INC (LXRX) is 4 / 10.